Home

kiling Nyttig vær stille varthalitis ioannis researchgate Vanlig oppløftet Presse ned

Ioannis BOUKOVINAS | Bioclinic Thessaloniki, Thessaloníki | Oncology Unit
Ioannis BOUKOVINAS | Bioclinic Thessaloniki, Thessaloníki | Oncology Unit

Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept

Effects of caspase inhibitors and thiol supplements on doxorubicin... |  Download Scientific Diagram
Effects of caspase inhibitors and thiol supplements on doxorubicin... | Download Scientific Diagram

Ioannis VARTHALITIS · Head of Department · 1st Medical Oncology Dept
Ioannis VARTHALITIS · Head of Department · 1st Medical Oncology Dept

Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept

Ioannis GIOULBASANIS | Head | MD, PhD | CHemotherapy
Ioannis GIOULBASANIS | Head | MD, PhD | CHemotherapy

Overall survival by RDI. Kaplan Meier overall survival curve for... |  Download Scientific Diagram
Overall survival by RDI. Kaplan Meier overall survival curve for... | Download Scientific Diagram

PDF) FEC versus sequential docetaxel followed by  epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary  node-positive early breast cancer: a randomized study of the Hellenic  Oncology Research Group (HORG) | I. Varthalitis
PDF) FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG) | I. Varthalitis

Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept

a Number of delayed cycles (\2 cycles, C2 cycles), b number of delayed... |  Download Scientific Diagram
a Number of delayed cycles (\2 cycles, C2 cycles), b number of delayed... | Download Scientific Diagram

Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept

Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept

Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept

Œ½¼± •€¯¸µ„   ±½/¼¹ Athanasios Krystallis Aarchus Univ  ... Athanasios Krystallis
Œ½¼± •€¯¸µ„  ±½/¼¹ Athanasios Krystallis Aarchus Univ ... Athanasios Krystallis

Ioannis BOUKOVINAS | Bioclinic Thessaloniki, Thessaloníki | Oncology Unit
Ioannis BOUKOVINAS | Bioclinic Thessaloniki, Thessaloníki | Oncology Unit

Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept

Endogenous and Exogenous Risk Factors of Patients Surveyed for... |  Download Table
Endogenous and Exogenous Risk Factors of Patients Surveyed for... | Download Table

Unadjusted (Observed) and Case Mix-Adjusted Prevalence Rates for... |  Download Table
Unadjusted (Observed) and Case Mix-Adjusted Prevalence Rates for... | Download Table

PDF) Case-Mix Adjustment Approach to Benchmarking Prevalence Rates of  Nosocomial Infection in Hospitals in Cyprus and Greece
PDF) Case-Mix Adjustment Approach to Benchmarking Prevalence Rates of Nosocomial Infection in Hospitals in Cyprus and Greece

Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept

Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept

I. Varthalitis's research works | Hellenic Cooperative Oncology Group,  Athens (HeCOG) and other places
I. Varthalitis's research works | Hellenic Cooperative Oncology Group, Athens (HeCOG) and other places

PDF) A multicenter phase II study of pegylated liposomal doxorubicin in  combination with irinotecan as second-line treatment of patients with  refractory small-cell lung cancer
PDF) A multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer

Univariate and Multivariate Analysis of Risk Factors for Mortality... |  Download Table
Univariate and Multivariate Analysis of Risk Factors for Mortality... | Download Table

REMARK diagram for biomarker studies. | Download Scientific Diagram
REMARK diagram for biomarker studies. | Download Scientific Diagram

Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept
Ioannis VARTHALITIS | Head of Department | 1st Medical Oncology Dept